Drugs / ADALIMUMAB FOSIMDESONIDE
ADALIMUMAB FOSIMDESONIDE
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05556226 | Oct 2022 → Feb 2023 | — | AbbVie | Completed | No outcome recorded |
| Phase 23 trials · 3 met primary | ||||||
| Phase 2 | NCT05068284 | Jan 2022 → Jul 2023 | Crohn disease | AbbVie | Terminated | Met primary Stop: Business |
| Phase 2 | NCT04972968 | Sep 2021 → Jul 2023 | polymyalgia rheumatica | AbbVie | Terminated | Met primary Stop: Business |
| Phase 2 | NCT04888585 | Jun 2021 → Aug 2022 | rheumatoid arthritis | AbbVie | Terminated | Met primary Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADALIMUMAB FOSIMDESONIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314652 ↗ |
| Known as | ABBV-154 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04888585 ↗ |
| Known as | Adalimumab fosimdesonida | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314652 ↗ |
| Route | Subcutaneous | “Subcutaneous Injection” NCT04888585 ↗ |